1. Volume 18, Issue 3, Pages 333-340 (September 2013)
The Effects of LY , an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes 
Gregory Gaich, Jenny Y. Chien, Haoda Fu, Leonard C. Glass, Mark A. Deeg, William L. Holland, Alexei Kharitonenkov, Thomas Bumol, Holger K. Schilske, David E. Moller 
Cell Metabolism 
Volume 18, Issue 3, Pages (September 2013)
DOI: /j.cmet
Copyright © 2013 Elsevier Inc. Terms and Conditions

2. Figure 1
Trial Profile
Numbers of subjects initially screened and subsequently randomized to each of four treatment groups are depicted. Subject disposition (number of subjects who discontinued treatment or completed the study) are also shown.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2013 Elsevier Inc. Terms and Conditions

3. Figure 2 Effect of LY2405319 on Triglycerides and LDL-Cholesterol
Time course of mean (±SEM) change from baseline in fasting plasma TGs (A) and LDL-C (B). ∗p < 0.05 from baseline, †p < 0.05 from placebo.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2013 Elsevier Inc. Terms and Conditions

4. Figure 3
Effect of LY on Body Weight and Selected Metabolic Parameters
Mean change from baseline (±SEM) in fasting glucose, insulin, adiponectin, and body weight. ∗p < 0.05 from baseline, and †p < 0.05 from placebo.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2013 Elsevier Inc. Terms and Conditions